These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 17941761)

  • 1. [Cost reduction in the treatment of Gaucher s disease].
    García Salom P; Acedo A
    Farm Hosp; 2007; 31(3):194-5. PubMed ID: 17941761
    [No Abstract]   [Full Text] [Related]  

  • 2. Extended remission of B-cell lymphoma with monoclonal gammopathy in a patient with type 1 Gaucher disease treated with enzyme replacement therapy.
    Camou F; Viallard JF
    Blood Cells Mol Dis; 2012 Jan; 48(1):51-2. PubMed ID: 21983348
    [No Abstract]   [Full Text] [Related]  

  • 3. Imino sugar therapy for type 1 Gaucher disease.
    Priestman DA; Platt FM; Dwek RA; Butters TD
    Glycobiology; 2000 Nov; 10(11):iv-vi. PubMed ID: 11221677
    [No Abstract]   [Full Text] [Related]  

  • 4. Gaucher disease: hematologic and oncologic implications.
    Hughes D
    Clin Adv Hematol Oncol; 2011 Oct; 9(10):771-2. PubMed ID: 22252578
    [No Abstract]   [Full Text] [Related]  

  • 5. [Financing of enzyme treatment in Gaucher disease].
    Wisløff F
    Tidsskr Nor Laegeforen; 2003 Feb; 123(3):364. PubMed ID: 12640908
    [No Abstract]   [Full Text] [Related]  

  • 6. Patients with Gaucher type 1: Switching from imiglucerase to miglustat therapy.
    Canda E; Kose M; Kagnici M; Ucar SK; Sozmen EY; Coker M
    Blood Cells Mol Dis; 2018 Feb; 68():180-184. PubMed ID: 28111116
    [No Abstract]   [Full Text] [Related]  

  • 7. [Osteoarticular manifestations of Gaucher disease in adults: pathophysiology and treatment].
    Hachulla E; Javier RM
    Rev Med Interne; 2007 Oct; 28 Suppl 2():S180-2. PubMed ID: 18228685
    [No Abstract]   [Full Text] [Related]  

  • 8. Therapeutic goals in Gaucher disease.
    Mistry P; Germain DP
    Rev Med Interne; 2006 Mar; 27 Suppl 1():S30-8. PubMed ID: 16644400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Gaucher disease].
    Iversen PO; Wisløff F
    Tidsskr Nor Laegeforen; 2003 Feb; 123(3):304-7. PubMed ID: 12640894
    [No Abstract]   [Full Text] [Related]  

  • 10. Low-dose versus high-frequency regimens in Gaucher's disease.
    Maródi L
    Lancet; 1995 Nov; 346(8987):1434. PubMed ID: 7475855
    [No Abstract]   [Full Text] [Related]  

  • 11. Alglucerase: the debate continues.
    Push S
    Pharmacoeconomics; 1995 Mar; 7(3):268-9. PubMed ID: 10155316
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness controversy.
    Cox TM
    Pharmacoeconomics; 1995 Jul; 8(1):82-3. PubMed ID: 10155604
    [No Abstract]   [Full Text] [Related]  

  • 13. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement.
    Elstein D; Dweck A; Attias D; Hadas-Halpern I; Zevin S; Altarescu G; Aerts JF; van Weely S; Zimran A
    Blood; 2007 Oct; 110(7):2296-301. PubMed ID: 17609429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of bone involvement in Gaucher diseases with imiglucerase combined with miglustat].
    Marie I
    Presse Med; 2009 Dec; 38 Suppl 2():2S68-70. PubMed ID: 20304314
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of Gaucher's disease with OGT 918.
    Mistry PK
    Lancet; 2000 Aug; 356(9230):676-7. PubMed ID: 10968454
    [No Abstract]   [Full Text] [Related]  

  • 16. The cost of treating Gaucher disease.
    Beutler E
    Nat Med; 1996 May; 2(5):523-4. PubMed ID: 8616707
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical study of the French cohort of Gaucher disease patients].
    Stirnemann J
    Rev Med Interne; 2006 Mar; 27 Suppl 1():S18-21. PubMed ID: 16644396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Osteoarticular manifestations of Gaucher disease in adults: pathophysiology and treatment].
    Javier RM; Hachulla E
    Presse Med; 2007 Dec; 36(12 Pt 3):1971-84. PubMed ID: 17498916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic objectives in Gaucher disease].
    Mistry P; Germain DP
    Rev Med Interne; 2007 Oct; 28 Suppl 2():S171-5. PubMed ID: 18228683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managing public payment for high-cost, high-benefit treatment: enzyme replacement therapy for Gaucher's disease in Ontario.
    Clarke JT; Amato D; Deber RB
    CMAJ; 2001 Sep; 165(5):595-6. PubMed ID: 11563212
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.